{
    "root": "45c5e31f-b268-49c7-869c-2422762fcc00",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "WINREVAIR",
    "value": "20250501",
    "ingredients": [],
    "indications": {
        "text": "winrevair\u2122 indicated treatment adults pulmonary arterial hypertension ( pah , world health organization [ ] group 1 ) increase exercise capacity , improve functional class ( fc ) , reduce risk worsening events .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting dose 0.3 mg/kg subcutaneous injection . ( 2.1 ) recommended target dose 0.7 mg/kg every 3 weeks subcutaneous injection . ( 2.2 ) modifications due increased hemoglobin ( hgb ) decreased platelets may necessary . check hgb platelets dose first 5 doses , longer values unstable , monitor periodically thereafter . ( 2.3 ) full prescribing information preparation instructions . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "winrevair ( sotatercept-csrk ) injection white off-white lyophilized cake powder appearance supplied single-dose vials ( 45 mg 60 mg ) packaged kits contain one measuring syringe one safety needle . kit also contains sterile water injection prefilled syringes necessary reconstitute product , vial adapter ( ) , alcohol pads , shown table 5. table 5 : kit contents kit vialadapters alcohol pads sterile water injection prefilled syringes ndc ( 1 ) 45 mg vial 1 4 ( 1 ) 1 ml syringe ndc # 0006-5090-01 ( 1 ) 60 mg vial 1 4 ( 1 ) 1.3 ml syringe ndc # 0006-5091-01 ( 2 ) 45 mg vials 2 8 ( 2 ) 1 ml syringes ndc # 0006-5087-01 ( 2 ) 60 mg vials 2 8 ( 2 ) 1.3 ml syringes ndc # 0006-5088-01",
    "adverseReactions": "none .",
    "indications_original": "WINREVAIR\u2122 is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.",
    "contraindications_original": "The recommended starting dose is 0.3 mg/kg by subcutaneous injection. ( 2.1 ) The recommended target dose is 0.7 mg/kg every 3 weeks by subcutaneous injection. ( 2.2 ) Dosage modifications due to increased hemoglobin (Hgb) and decreased platelets may be necessary. Check Hgb and platelets before each dose for the first 5 doses, or longer if values are unstable, and monitor periodically thereafter. ( 2.3 ) See full prescribing information for preparation and administration instructions. ( 2.4 )",
    "warningsAndPrecautions_original": "WINREVAIR (sotatercept-csrk) for injection is a white to off-white lyophilized cake or powder appearance supplied in single-dose vials (45 mg or 60 mg) packaged in kits that contain one measuring syringe and one safety needle. Each kit also contains Sterile Water for Injection in prefilled syringes necessary to reconstitute the product, vial adapter(s), and alcohol pads, as shown in Table 5.\n                        \n                           Table 5: Kit Contents\n                           \n                           \n                           \n                           \n                           \n                           \n                              \n                                 Kit\n                                 VialAdapters\n                                 Alcohol Pads\n                                 Sterile Water for Injection in prefilled syringes\n                                 NDC\n                              \n                           \n                           \n                              \n                                 (1) 45 mg vial\n                                 1\n                                 4\n                                 (1) 1 mL syringe\n                                 NDC # 0006-5090-01\n                              \n                              \n                                 (1) 60 mg vial\n                                 1\n                                 4\n                                 (1) 1.3 mL syringe\n                                 NDC # 0006-5091-01\n                              \n                              \n                                 (2) 45 mg vials\n                                 2\n                                 8\n                                 (2) 1 mL syringes\n                                 NDC # 0006-5087-01\n                              \n                              \n                                 (2) 60 mg vials\n                                 2\n                                 8\n                                 (2) 1.3 mL syringes\n                                 NDC # 0006-5088-01",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "WINREVAIR"
        }
    ]
}